Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.
- Pivotal Phase 3 LUCIDITY trial will evaluate FDA-agreed upon primary outcome of reduction in hypoglycemia events and designed to align as closely as possible with previous Phase 2 trial designs...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the 7th Annual Evercore ISI HealthCONx Conference. The conference is...
On track to initiate a Phase 3 program for Company’s lead asset avexitide, a GLP-1 receptor antagonist with FDA Breakthrough Therapy and Orphan Drug Designations, in post-bariatric hypoglycemia...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its third quarter 2024 financial results on Thursday, November 7, 2024. Amylyx’ senior management team will...
- Improvement observed in pancreatic function, as measured by C-peptide response, following 24 weeks of treatment with AMX0035; worsening is typically expected with disease progression based on...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the Company will host a virtual webcast on October 17, 2024 at 1:30 p.m. ET with management and Fumihiko...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.32 | -7.32265446224 | 4.37 | 4.49 | 3.78 | 989454 | 4.05881524 | CS |
| 4 | -1.28 | -24.0150093809 | 5.33 | 5.85 | 3.78 | 799712 | 4.77689319 | CS |
| 12 | 0.8 | 24.6153846154 | 3.25 | 7.27 | 2.9101 | 1341956 | 4.84634309 | CS |
| 26 | 2.43 | 150 | 1.62 | 7.27 | 1.62 | 1441021 | 3.35287853 | CS |
| 52 | -10.23 | -71.6386554622 | 14.28 | 19.9488 | 1.575 | 1863080 | 4.89640992 | CS |
| 156 | -16.95 | -80.7142857143 | 21 | 41.9297 | 1.575 | 1343090 | 14.80761545 | CS |
| 260 | -16.95 | -80.7142857143 | 21 | 41.9297 | 1.575 | 1343090 | 14.80761545 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
